{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T07:47:39Z","timestamp":1665128859241},"reference-count":32,"publisher":"Baishideng Publishing Group Inc.","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3748\/wjg.v22.i38.8558","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T22:18:08Z","timestamp":1476224288000},"page":"8558","source":"Crossref","is-referenced-by-count":5,"title":["Retrospective analysis of hepatitis C infected patients treated through an integrated care model"],"prefix":"10.3748","volume":"22","author":[{"given":"James M","family":"Levin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Dabirshahsahebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Huckins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"Holtzman D. traveler’s health. Chapter 3. Infectious diseases related to travel. Hepatitis C. last updated July 10. 2015; Available from: http:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2016\/infectious-diseases-related-to-travel\/hepatitis-c<\/ext-link>."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28026"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2015.05.004"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"ref5","unstructured":"Chopra S, Pockris P. Overview of the management of chronic hepatitis C virus infection. Available from: http:\/\/www-uptodate-com.ezproxy.library.wisc.edu\/contents\/overview-of-the-management-of-chronic-hepatitis-c-virus-infection?source=preview&search=hepatitisc&language=en-US&anchor=H1&selectedTitle=1~150#H1<\/ext-link>."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27366"},{"key":"ref7","unstructured":"Pockros P. Direct-acting antivirals for the treatment of hepatitis C virus infection. Available from: http:\/\/www-uptodate-com.ezproxy.library.wisc.edu\/contents\/direct-acting-antivirals-for-the-treatment-of-hepatitis-c-virus-infection?source=machineLearning&search=directactingantivirals&selectedTitle=1~150§ionRank=5&anchor=H1818005026#H1818005026<\/ext-link>."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01617.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1297928"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp388"},{"key":"ref11","unstructured":"Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. Available from: http:\/\/www.hcvguidelines.org<\/ext-link>."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12764"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0748-8"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2013.19.6.438"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28467"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Lawitz EJ, Ruane P, Stedman C, Foster G, Hyland RH, Coogan S, Moody S, Dvory-Sobol H, Knox SJ, Brainard DM, Abergel A, Agarwal K, Younes Z, Schwabe C. Long-term follow-up of patients with chronic HCV infection following treatment with direct acting antiviral regimens: maintenance of SVR, persistence of resistance mutations and clinical outcomes. Paper presented at the European Association for the Study of the Liver meeting; 2016 Apr 15; Barcelona, Spain. Abstract FRI-166. .","DOI":"10.1016\/S0168-8278(16)01134-X"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28422"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.10.013"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Cohen M, Kahan NR, Waitman D, Tur-Kaspa R. An interim analysis of a national program for treating hepatitis c with novel antiviral agents. The European Association for the Study of the Liver, The International Liver Congress 2016; Barcelona, Spain. .","DOI":"10.1016\/S0168-8278(16)00777-7"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Lai J, Witt M, Witt D. Real-word effectiveness of 8, 12 and 24 weeks ledipasvir (LDV)\/sofosbuvir (SOF)-based therapy for hepatitis c virus (HCV) genotype 1: analysis in a large integrated health care system. The European Association for the Study of the Liver, The International Liver Congress 2016; Barcelona, Spain. .","DOI":"10.1016\/S0168-8278(16)01517-8"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00052-9"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"ref31","unstructured":"Kamble PS, Walker DR, Marx S, Harvey R, Uribe CL, Bunniran S, Collins J. Adherence and discontinuation rates of sofosbuvir-based regimens: modeling real world experience in a large managed care organization. Paper presented at: The American Association for the Study of Liver Diseases Liver Meeting; 2015 Nov 15; San Francisco, CA. Abstract 1050. ."},{"key":"ref32","unstructured":"Marra F, Leber W, Barclay ST, Christensen S, Ouzan D, Oules V, McMahon PS, Kostev K, Ansolabehere X. High prevalence of co-morbidities and complex polypharmacy with drug-drug interaction (DDI) potential in patients with chronic Hepatitis C (CHC). Consistent findings from large primary care databases in the United Kingdom, Germany, and France. Paper presented at: The American Association for the Study of Liver Diseases Liver Meeting; 2015 Nov 15; San Francisco, CA. Abstract 1052. ."}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i38\/8558.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T09:29:55Z","timestamp":1568453395000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i38\/8558.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":32,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v22.i38.8558","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}